Can AMH Predict Menopause? What One Blood Test Can’t Tell You

Women searching "when will I hit menopause?" often find AMH sold as a personal countdown clock. The hormone does track the shrinking pool of ovarian follicles, and it falls sharply before the final menstrual period. But a single AMH result cannot reliably tell an individual woman when menopause will begin. The biology is real; the precision marketing is ahead of the evidence.

A 2023 systematic review by Nelson et al., covering 41 longitudinal and cross-sectional studies with 28,858 participants, reached the useful middle ground. AMH declines before menopause and becomes undetectable afterward, so it is a valid marker of ovarian reserve. Yet models based on AMH still produce prediction intervals too wide for confident, individual menopause-date counseling.

That distinction matters most in your late 30s and early 40s, when a number can feel alarmingly personal. A low or low-normal result may warrant context and, in some cases, medical evaluation. It does not turn a laboratory report into a calendar.

What AMH measures

Anti-Müllerian hormone is produced by granulosa cells in small pre-antral and antral follicles. Its blood concentration reflects the remaining primordial follicle pool: the ovarian reserve. Follicle loss begins before birth, continues through reproductive life, and accelerates as menopause approaches. A 2025 review of ovarian aging describes this underlying trajectory and why AMH falls as the follicle pool contracts.

AMH has a practical advantage over several reproductive hormones: it varies less across the menstrual cycle than FSH and inhibin B. That makes a single blood draw easier to schedule. Easier to measure, however, does not mean easier to interpret.

AMH is also not a direct measure of egg quality, a diagnosis of infertility, or a guaranteed forecast of natural conception. In a 2022 systematic review and meta-analysis of 11 studies involving 4,388 women attempting natural conception, AMH had limited predictive value for clinical pregnancy, with a summary AUC of 0.5932. Ovarian reserve and the odds of conceiving in a given month are related questions, but they are not interchangeable.

AMH can identify a biological transition, not date it precisely

The strongest evidence supports AMH as a marker of ovarian aging. In longitudinal ALSPAC data summarized by Nelson and colleagues, AMH declined steeply before menopause. The same figure showed wide 95% confidence intervals. Those intervals are the central practical limitation: women of the same age with the same AMH value can reach their final menstrual period years apart.

The systematic review did not provide numerical, age-stratified prediction windows that would justify telling a 38-year-old she is, for example, a specified number of years from menopause. The evidence does show population-level signal. It does not support individual-level certainty.

A 2022 review by de Kat et al. reached the same conclusion. AMH-based models can predict menopause at the population level, but their individual prediction intervals remain too wide for actionable counseling, especially in women under 40. This is exactly the age group most likely to seek a forecast before their cycles become irregular.

Small longitudinal studies suggest that trends may eventually prove more informative than a single result. In de Vet et al.'s prospective cohort of 54 women, followed for a mean of 2.6 years, median AMH fell significantly from 2.1 µg/L to 1.3 µg/L. Antral follicle count, FSH, and inhibin B did not significantly change over the same period. The result suggests that serial AMH can detect an early decline that other markers miss. But only 41 participants were premenopausal, follow-up was short, and the study predates current assay standardization. It does not establish a validated monitoring schedule or a threshold that predicts menopause for one person.

Age still does much of the predictive work

AMH declines with age, which creates an awkward but necessary question: how much does the blood test add beyond knowing someone's age? In a cross-sectional study of 288 women summarized in the Nelson review, Zhang et al. found that chronological age had a greater independent effect on AMH concentration than menopausal stage.

That finding cannot prove that age causes every difference in AMH. Cross-sectional studies can be affected by cohort effects and survival bias. Still, it weakens claims that AMH supplies a wholly separate, high-precision signal about menopause timing. A woman's age, cycle pattern, symptoms, family history, and relevant medical history remain central to counseling.

The markers also overlap biologically. A 2021 analysis by Robertson et al. examined the relationship among AMH, FSH, inhibin B, and antral follicle count in late reproductive age. AMH suppresses FSH sensitivity to follicular depletion, so AMH and FSH are not independent messages arriving from unrelated parts of the body. Reading AMH in isolation can overstate what one result adds.

For current menopause status, AMH is not the best test

AMH performs reasonably well for the binary question of whether menopause has already occurred. In Shin et al.'s 2008 dataset of 144 participants, AMH had an AUROC of 0.943; it was undetectable in 20 of 33 confirmed postmenopausal women, or 61%.

In that same dataset, FSH performed better. An FSH threshold above 22.3 mIU/mL had an AUROC of 0.998, while LH above 8.7 mIU/mL had an AUROC of 0.996. Those results do not make AMH useless. They show that for diagnosing current menopausal status, established hormonal markers outperformed it in this comparison.

Different AMH assays add another complication. Studies in the systematic review used platforms including EIA Immunotech, DSL Active MIS ELISA, and Beckman Coulter Access AMH. Calibration differences can shift cutoff values, so a threshold from one study cannot simply be copied onto a result from another laboratory. A lab number without its assay context is less portable than consumer testing ads imply.

When a low AMH result needs medical attention

The important clinical use case is possible premature ovarian insufficiency (POI), meaning menopause before age 40. Nelson and colleagues estimate that POI affects about 4% of women; early menopause before age 45 affects about 8%. POI can accelerate bone loss and raise cardiovascular and metabolic risk, and hormone therapy can address important long-term consequences.

AMH can support an evaluation for POI because values often approach the assay's detection limit when ovarian reserve is severely depleted. It cannot diagnose POI by itself. The 2024 International Menopause Society guideline led by Panay et al. requires amenorrhea plus confirmed FSH elevation over at least four months. A near-undetectable AMH in an asymptomatic woman under 35 calls for clinical correlation and follow-up, not a diagnosis delivered by an app.

Seek medical assessment promptly for persistent irregular or absent periods before age 45, especially with hot flashes, night sweats, mood changes, prior chemotherapy or pelvic radiation, ovarian surgery, or a family history of early menopause. A clinician may use FSH, LH, estradiol, AMH, and other evaluation tailored to the situation. The result should guide care, including bone-health assessment and discussion of hormone therapy when POI is diagnosed.

What AMH does not answer yet

Parity, breastfeeding history, bone outcomes, and hot flashes are all plausible topics for ovarian-aging research, but the available cohort evidence does not establish specific AMH associations for those outcomes. AMH should not be treated as a substitute for symptom assessment, menstrual history, or bone-risk evaluation.

Major guidelines do not recommend routine AMH testing to predict menopause in asymptomatic women. The reason is not that AMH is fictional. It is that no well-powered prospective study has shown that AMH-guided counseling improves health outcomes over age-informed standard care.

A single low-normal AMH result in a healthy 38-year-old is one data point with wide uncertainty, not a menopause appointment.

If you are considering proactive testing solely to learn your menopause date, the evidence does not support it. If you have symptoms or risk factors for early ovarian insufficiency, AMH can be a useful supporting test within a full clinical workup. For everyone else, treat the result as a reserve marker with limits—not a crystal ball with a lab logo.